This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

A Double-Blind Comparison of Fluvoxamine and Paroxetine in the Treatment of Depressed Outpatients

Ari Kiev and Alan Feiger

Published: April 15, 1997

Article Abstract

Background: Fluvoxamine and paroxetine, both serotonin selective reuptake inhibitors (SSRIs), were compared at two centers in a 7week doubleblind study in outpatients with major depression, diagnosed by DSMIIIR criteria.

Method: Sixty patients were randomly assigned to receive dosage titrated upward to between 50_150 mg/day of fluvoxamine (N=30) or 20_50 mg/day of paroxetine (N=30). The mean±SD daily dose administered at the last assessment was 102±44 mg/day for fluvoxamine and 36±13 mg/day for paroxetine. Sixteen (53%) fluvoxamine-treated patients and 10 (33%) paroxetine-treated patients were titrated to the maximum permissible dosage of either drug. Sample size was calculated to provide at least 85% power at 5% level of significance to detect at least a 1.00-point difference in mean severity of adverse events, assuming a standard deviation of 1.0.

Results: Fluvoxamine and paroxetine were similarly effective in ameliorating depression as demonstrated by mean total scores of 10.9±7.3 (p

Conclusion: Observed differences in some side effects, although not statistically significant, indicate that when a patient has difficulty tolerating one SSRI, the clinician may choose to change to a different agent within the same class.

Volume: 58

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF